Hikma Pharmaceuticals PLC
Deschisă
SectorSănătate
1,531 0.53
Rezumat
Modificarea prețului
24h
Minim
1515
Maxim
1536
Venit | 165M |
|---|---|
Vânzări | 41M 1.7B |
P/E Medie Sector | 10.891 50.958 |
EPS | 1.07 |
Randament dividend | 5.65 |
Marjă de profit | 9.698 |
Angajați | 9,400 |
EBITDA | 152M 411M |
Recomandări | Cumpărare |
|---|---|
Prognoză pe 12 luni | +14.11% upside |
Randament dividend Medie Sector | 5.65% 2.41% |
|---|---|
Următoarele câștiguri | 6 aug. 2026 |
Data viitoare de dividende | 17 sept. 2026 |
Următoarea dată ex-dividende | 13 aug. 2026 |
Capitalizare de piață | -476M 3.2B |
|---|---|
Deschiderea anterioară | 1530.47 |
Închiderea anterioară | 1531 |
Sentimentul știrilor
By Acuity
17%
83%
28 / 342 Clasament în Healthcare
Hikma Pharmaceuticals PLC Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Despre Hikma Pharmaceuticals PLC
Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including respiratory, oncology, and pain management. It also offers its products in solid, semi-solid, liquid, and injectable final dosage forms. The company operates in the United Kingdom, rest of Europe, North America, the Middle East, North Africa, and internationally. Hikma Pharmaceuticals PLC was founded in 1978 and is headquartered in London, the United Kingdom.